Salute e Benessere

Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting…

Interim data from the IQIRVO ®(elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in improvement of fatigue and pruritus symptoms, with a well-characterized safety profile over more than three years of treatment Additional new data from the ELATIVE trial highlights the potential for IQIRVO, a PPAR α/δ agonist, to beneficially impact fatigue-associated pathways linked to...
Nasdaq GlobeNewswire
07/11/2025

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, Nov.07, 2025(GLOBE NEWSWIRE) --Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim 2nd Annual Healthcare Innovation ConferenceDate: Wednesday, November 12, 2025Fireside Chat: 10:30 AM ET Event: Jefferies Global Healthcare...
Nasdaq GlobeNewswire
07/11/2025

Dr. Adrian Bot joins Immuthera to support the company with his unique experience…

Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapiesDr. Adrian Bot, a renowned biopharmaceutical founder and scientist, has joined Immuthera’s Board of Directors to strengthen its pipeline development and commercialization efforts.Immuthera, operating in the United States, is a wholly owned subsidiary of PolTREG S.A. a leader in innovative immune therapies with focus on regulatory T cell technologies...
Nasdaq GlobeNewswire
07/11/2025

Resolution Therapeutics announces new data showcasing the potential of…

First poster: Early modulation of liver function biomarkers INR and MELD is associated with positive long term clinical outcomes in patients with cirrhosis First poster: Early modulation of liver function biomarkers INR and MELD is associated with positive long term clinical outcomes in patients with cirrhosis DrPaul Brennan, Clinical Lecturer in Hepatology at theUniversity of Dundee, UK, will present a poster titled " Early modulation of INR and MELD after regenerative macrophage...
PR Newswire
07/11/2025

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all…

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion, and nasal polyps in patients aged 6 years and older compared to placeboDupixent sBLA accepted for priority review by the US FDA with a...
Nasdaq GlobeNewswire
07/11/2025

Notification of managers’ transactions

ANNOUNCEMENT NO. 298 7 November 2025Notification of managers’ transactionsChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.See the transactions of CFO Kim Nicolajsen in the attached PDF document.For further information, please contact:Kim Nicolajsen, CFO...
Nasdaq GlobeNewswire
07/11/2025

Notification of managers’ transactions

ANNOUNCEMENT NO. 297 7 November 2025Notification of managers’ transactionsChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.See the transactions of CEO Martin Helbo Behrens in the attached PDF document.For further information, please contact:Kim Nicolajsen,...
Nasdaq GlobeNewswire
07/11/2025

138th Canton Fair: China's Apparel Industry Threads a New Path with Innovation…

Innovation in functional design also took center stage. A manufacturer from Jilin introduced heated apparel incorporating built-in electric elements to provide active warmth for cold environments. This product has already gained strong traction in the U.S. market. The company's cooling garments, designed with advanced ventilation components, offer comfort in hot climates and are gradually expanding into European and American markets. The company's fashion-forward workwear line, which merges…
PR Newswire
07/11/2025

Black November Surge: Flooring365.co.uk Responds to Seasonal Renovation Boom…

As winter renovations continue to trend upwards, particularly in the run-up to Christmas, this extended sale aims to help homeowners upgrade their floors with quality materials—without the usual price tag. As winter renovations continue to trend upwards, particularly in the run-up to Christmas, this extended sale aims to help homeowners upgrade their floors with quality materials—without the usual price tag. "November is always a key time for renovations, and we know people are keen to...
PR Newswire
07/11/2025

Major shareholder announcement

Please read the full announcement in PDFAttachments 2025_47_Major_Shareholders_AnnouncementNovozymes B 05 November 2025_Final
Nasdaq GlobeNewswire
07/11/2025

SciBase: Interim report

The third quarter in figures The third quarter in figures The first nine months in figures Important events during the quarter Important events after the end of the period This information is information that SciBase Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on7 November 2025. This report has been...
PR Newswire
07/11/2025

The Board of Directors in SciBase resolves on an offer to repurchase outstanding…

Summary of the TO 2 Offer Summary of the TO 2 Offer Summary of the Rights Issue "SciBase is developing well with a growing and profitable operation inGermanyand rapid growth in the US. In addition to our strong performance within melanoma diagnostics, we are accelerating our activities in other skin diseases together with Castle Biosciences. The upcoming Rights Issue will provide runway for continued growth that will set us on a course towards profitability. There is a strong...
PR Newswire
07/11/2025

SciBase and Castle Biosciences expand collaboration and license agreement and…

"Our collaboration with Castle Biosciences is moving ahead at full speed," said Pia Renaudin, CEO of SciBase. "With this loan, we secure the resources needed to smoothly ramp up production and maintain uninterrupted growth. We expect the resulting improvements in product margins will create value across all markets and indications. This collaboration will also help us accelerate the adoption of Nevisense in skin barrier health and continue driving strong sales growth in skin…
PR Newswire
07/11/2025

Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE…

PRESS RELEASE Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Resource Utilization of Managing Kidney Transplant Recipients at ASN Kidney Week MeetingLong term follow-up data shows a sustained and improved (vs. week 20) benefit of potravitug on BK polyomavirus viral load in kidney transplant recipients at week 38 (study end)Potravitug was well tolerated, with no treatment related...
Nasdaq GlobeNewswire
07/11/2025

Coway Announces Financial Results for Q3 FY2025

Coway's reported earnings are as follows: Coway's reported earnings are as follows: Coway's cumulative revenue for 2025 has now reachedKRW 3,688.2 billion(+15.8% YoY), with an operating profit ofKRW 697.0 billion(+13.9%). Within the domestic market, Coway achieved a third-quarter revenue ofKRW 740.2 billion, a 12% increase when compared with the same period last year. This strong performance was driven by robust sales of the new Icon Ice Water Purifier series, which features...
PR Newswire
07/11/2025

Endometrial Cancer Market Poised for Expansion Throughout Forecast Period…

Endometrial Cancer Market Summary Endometrial Cancer Market Summary Discover the endometrial cancer new treatment @New Treatments for Endometrial Cancer Key Factors Driving the Growth of the Endometrial Cancer Market Rising incidence driven by demographic and lifestyle factors Ageing populations plus increases in obesity and metabolic conditions are raising endometrial cancer incidence in many regions — a larger patient pool increases demand for diagnostics, treatment...
PR Newswire
06/11/2025

Combined General Meeting of November 27, 2025 - Availability of the preparatory…

Daix (France), New York City (New York, United States), November 6, 2025– Inventiva (Euronext Paris and Nasdaq : IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the availability of the preparatory documents for the Combined General Meeting of November 27, 2025.Shareholders are invited to participate in the...
Nasdaq GlobeNewswire
06/11/2025

Alkermes to Participate in Two Upcoming Investor Conferences

Jefferies Global Healthcare Conference in LondonDate/Time:Wednesday, Nov. 19, 2025 at 11:30 a.m. ET (4:30 p.m. GMT) Jefferies Global Healthcare Conference inLondonDate/Time:Wednesday, Nov. 19, 2025at11:30 a.m. ET( 4:30 p.m. GMT ) The live webcasts may be accessed under the Investors tab onwww.alkermes.comand will be archived for 14 days. About Alkermes plc Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that...
PR Newswire
06/11/2025

Statement of total voting rights and shares forming the company’s share capital…

Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www .inventivapharma.com DateNumber of Shares Outstanding Total voting rights,gross(1) Total voting rights,net(2)October 20 th, 2025145 951 274158 653 570158 594 019(1) The total number of gross (or “theoretical”) voting rights is used as the basis for...
Nasdaq GlobeNewswire
06/11/2025

Novo Nordisk's CagriSema was associated with significant reduction in blood…

"We're very excited by the results of these analyses of CagriSema, which show promising results of combining cagrilintide with the proven significant effects of semaglutide on CV health," said Martin Holst Lange, chief scientific officer and executive vice president of Research & Development at Novo Nordisk. "People living with obesity have treatment goals that often include both losing weight and improving overall health. That's why we continue to explore new therapies that…
PR Newswire
06/11/2025

Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to…

Obesity medicines coverage in U.S. Medicare Part D via a pilot programme, starting during 2026Introduction of lower prices for Novo Nordisk’s semaglutide medicines in U.S. Medicare Part D and Medicaid and in direct-to-patients cash channelNovo Nordisk currently expects an estimated negative low single-digit impact on global sales growth in 2026Bagsværd, Denmark, 6 November 2025– Today it was announced that Novo Nordisk has agreed with the U.S. Administration to lower drug prices...
Nasdaq GlobeNewswire
06/11/2025

EssilorLuxottica expands its myopia management platform with Essilor Stellest…

EssilorLuxottica expands its myopia management platform with Essilor Stellest 2.0 lenses, smart glasses and an innovative pre-myopia solutionParis, France (6 November 2025)– EssilorLuxottica today announced the evolution of its Essilor Stellest platform at the China International Import Expo (CIIE) in Shanghai. Building on the Group’s forty-five years of research and innovation in myopia management, the enhanced Essilor Stellest portfolio reinforces EssilorLuxottica’s commitment to...
Nasdaq GlobeNewswire
06/11/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from October 27 thto October 31 st2025 Name of the issueIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1127/10/2025...
Nasdaq GlobeNewswire
06/11/2025

Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data…

Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster at ASN kidney week, the world’s premier nephrology meetingVIVIAD analyses continue to support varoglutamstat’s potential in kidney disease, and consistently provide further evidence for a beneficial impact on kidney function based on its proposed mechanism...
Nasdaq GlobeNewswire
06/11/2025
Altri  Comunicati